"On the heels of the FDA's recent approval of the first over-the-counter opioid reversal agent [Narcan], the availability of nalmefene nasal spray places a new prescription opioid reversal option ...
“We’re not suffering from a naloxone shortage where we need to use an alternative,” he said. “We have plenty of it and it works perfectly well.” The FDA approval comes as drug overdose ...
Signage is seen outside of the Food and Drug Administration (FDA) headquarters ... on Monday approved Opiant Pharmaceuticals Inc's nasal spray for reversing opioid-related overdoses, expanding ...
The U.S. Food and Drug Administration has approved Brixadi (buprenorphine) extended-release injection to treat ...
“We’re not suffering from a naloxone shortage where we need to use an alternative,” he said. “We have plenty of it and it works perfectly well.” The FDA approval comes as drug overdose ...
“We’re not suffering from a naloxone shortage where we need to use an alternative,” he said. “We have plenty of it and it works perfectly well.” The FDA approval comes as drug overdose ...
(Reuters) - The U.S. Food and Drug Administration on Monday approved Opiant Pharmaceuticals Inc's nasal spray for reversing opioid-related overdoses, expanding treatment options in the country's fight ...
The Food and Drug Administration (FDA) approved a prescription nasal spray this week that can reverse opioid overdoses. Opvee is an almefene hydrochloride nasal spray that is the first of its kind ...
U.S. health regulators have approved a new nasal spray to reverse overdoses due to fentanyl and other powerful opioids WASHINGTON -- U.S. health regulators on Monday approved a new easy-to-use ...
U.S. health regulators have approved a new nasal spray to reverse overdoses due to fentanyl and other powerful opioids WASHINGTON -- U.S. health regulators on Monday approved a new easy-to-use ...
The Food and Drug Administration (FDA) approved a prescription nasal spray this week that can reverse opioid overdoses. Opvee is an almefene hydrochloride nasal spray that is the first of its kind to ...